FdaApplication
ANDA 212517
Identifiers
- fda_app_no: ANDA212517
Properties
| Property | Value |
|---|---|
| applicant_name | SCIEGEN PHARMACEUTICALS INC |
| application_type | ANDA |
| approval_date | 2020-02-21 |
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| NAPROXEN | NAPROXEN | 375MG | TABLET;ORAL |
| NAPROXEN | NAPROXEN | 500MG | TABLET;ORAL |
| NAPROXEN | NAPROXEN | 250MG | TABLET;ORAL |
3 products